ZEO ScientifiX (ZEOX) Stock Price

Organicell Regenerative Medicine Inc generates revenue through its clinical-stage biopharmaceutical products, primarily focusing on regenerative medicine solutions. The company's leading product, Zofin (Organicell Flow), is an acellular biologic therapeutic derived from perinatal sources, containing over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs. This product is administered through doctors and clinics in the healthcare industry, targeting degenerative diseases. The company has secured FDA approvals including IND and eIND, along with IRB authorizations, enabling its therapeutic applications. The company operates within the biotechnology sector, developing biological therapeutics for degenerative conditions. Zofin (Organicell Flow) serves as the core product, leveraging natural microRNAs and exosomes from perinatal tissues without additional substances. Healthcare providers and clinics are the primary buyers of this therapeutic, utilizing it for patient treatments under FDA-approved protocols. The product's unique composition supports its application in regenerative medicine, differentiating it in the market. Organicell Regenerative Medicine Inc's business model centers on the development and commercialization of Zofin (Organicell Flow), which is used in clinical settings for degenerative disease treatment. The company's focus on FDA-approved pathways through IND and eIND approvals ensures regulatory compliance for its product distribution. Healthcare professionals and clinics are the key segments purchasing the product, driven by its therapeutic benefits and natural composition derived from perinatal sources.